Business
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of
About this update from Fortress Biotech, Inc.
[{"type":"text","content":"U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024\nSCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that it will be exhibiting at the 2025 American Academy of Dermatology (“AAD”) Annual Meeting, taking place March 7-11, 2025 in Orlando, Florida. Journey Medical plans to highlight the launch of Emrosi™ and showcase its line of prescription dermatology products. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024. Interested parties are invited to visit Journey Medical’s booth 2181 to learn about Emrosi and the rest of its exciting portfolio of dermatology products. For more information, please visit https://journeymedicalcorp.com/. “We are thrilled to showcase our latest FDA-approved treatment, Emrosi, and present our portfolio of prescription dermatology products at the highly regarded AAD annual meeting,” said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical. “As the lowest-dose oral minocycline on the market, Emrosi delivers significantly superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profile. With our launch underway, we look forward to educating the dermatology community about this innovative treatment that is creating a new treatment paradigm for millions of patients with rosacea.” The AAD annual meeting is one of the leading dermatology conferences in the U.S., with over 350 exhibitors and close to 20,000 attendees, including more than 10,000 medical personnel, and more than 300 educational sessions. Founded in 1938 and headquartered in Rosemont, Illinois, AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails, advocating high standards in clinical practice, education, and research in dermatology, and supporting and enhancing patient care for ...